Richter BioLogics

Executive Summary

Richter BioLogics is a German Contract Development and Manufacturing Organization (CDMO) with over 35 years of expertise in microbial production of biopharmaceuticals. The company offers end-to-end services for recombinant proteins, peptides, antibody fragments, plasmid DNA, and bacterial vaccines using E. coli and Pichia expression systems. Operating three cGMP-compliant facilities in Germany, Richter serves a global client base from early-stage development through commercial supply. Its long-standing experience and focus on microbial platforms position it as a specialized partner in the rapidly growing biologics CDMO market. The CDMO market continues to benefit from increasing outsourcing trends by biopharma companies seeking cost efficiency and flexible capacity. Richter BioLogics is well-placed to capture demand for microbial-based therapeutics, including antibody fragments and plasmid DNA, driven by the rise of gene therapies and personalized medicine. However, as a private company with limited public disclosures, its growth trajectory depends on winning new contracts and expanding capacity. The company’s strong regulatory track record and existing infrastructure provide a solid foundation for sustained growth, though competition from larger CDMOs remains a challenge.

Upcoming Catalysts (preview)

• TBDCapacity expansion at existing facilities70% success
• TBDStrategic partnership with a mid-sized biotech for commercial supply60% success
• TBDIntroduction of a new microbial platform service (e.g., high-yield strain development)55% success